Antineoplastics/mesna
1
Reactions 1382 - 17 Dec 2011 S Antineoplastics/mesna Acute respiratory distress and renal failure: case report A 52-year-old man developed acute respiratory distress followed by acute renal failure while receiving cisplatin, etoposide, ifosfamide and mesna [routes not stated] for testicular cancer. The man started receiving a regimen containing cisplatin 20 mg/m 2 , etoposide 75 mg/m 2 , ifosfamide 1200 mg/m 2 and mesna 1200 mg/m 2 daily for 5 days. Within 24 hours, he developed acute respiratory distress. The man required intubation and mechanical ventilation. During chemotherapy, he developed acute anuric renal failure, thought to be tubular necrosis. His creatinine level was 338 µmol/L on day 8 and 508 µmol/L on day 10. The acute tubular necrosis was attributed to cisplatin and ifosfamide treatment, as well as tumour lysis syndrome. He received continuous haemofiltration from days 5–8 followed by intermittent dialysis. On day 27, a course of IV cisplatin for 5 days with etoposide 100 mg/m 2 and bleomycin was started, and he subsequently received two further courses of this regimen. In the first course, he received cisplatin at a dose of 8 mg/m 2 on days 1 and 2, 12 mg/m 2 on days 3 and 4 and 16 mg/m 2 on day 5. His renal function improved, with normal diuresis, and haemodialysis was stopped. For the next course of chemotherapy, his serum creatinine level was 184 µmol/L, and cisplatin was administered at 12 mg/m 2 on days 1 and 2 and 16 mg/m 2 on days 3–5. On the first day of the third course, his serum creatinine level had normalised (102 µmol/L). He received full doses of cisplatin (20 mg/m 2 /day) on days 1–5. His serum creatinine level stabilised at around 100 µmol/L. Pouliquen A-L, et al. Optimization of cisplatin doses in a testicular cancer patient with acute renal failure. Journal of Oncology Pharmacy Practice 17: 265-269, No. 3, Sep 2011. Available from: URL: http://dx.doi.org/10.1177/1078155209351761 - France 803064242 1 Reactions 17 Dec 2011 No. 1382 0114-9954/10/1382-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Transcript of Antineoplastics/mesna
Reactions 1382 - 17 Dec 2011
SAntineoplastics/mesna
Acute respiratory distress and renal failure: casereport
A 52-year-old man developed acute respiratory distressfollowed by acute renal failure while receiving cisplatin,etoposide, ifosfamide and mesna [routes not stated] fortesticular cancer.
The man started receiving a regimen containing cisplatin20 mg/m2, etoposide 75 mg/m2, ifosfamide 1200 mg/m2
and mesna 1200 mg/m2 daily for 5 days. Within 24 hours,he developed acute respiratory distress.
The man required intubation and mechanical ventilation.During chemotherapy, he developed acute anuric renalfailure, thought to be tubular necrosis. His creatinine levelwas 338 µmol/L on day 8 and 508 µmol/L on day 10. Theacute tubular necrosis was attributed to cisplatin andifosfamide treatment, as well as tumour lysis syndrome. Hereceived continuous haemofiltration from days 5–8followed by intermittent dialysis. On day 27, a course of IVcisplatin for 5 days with etoposide 100 mg/m2 andbleomycin was started, and he subsequently received twofurther courses of this regimen. In the first course, hereceived cisplatin at a dose of 8 mg/m2 on days 1 and 2,12 mg/m2 on days 3 and 4 and 16 mg/m2 on day 5. His renalfunction improved, with normal diuresis, andhaemodialysis was stopped. For the next course ofchemotherapy, his serum creatinine level was 184 µmol/L,and cisplatin was administered at 12 mg/m2 on days 1 and 2and 16 mg/m2 on days 3–5. On the first day of the thirdcourse, his serum creatinine level had normalised(102 µmol/L). He received full doses of cisplatin(20 mg/m2/day) on days 1–5. His serum creatinine levelstabilised at around 100 µmol/L.Pouliquen A-L, et al. Optimization of cisplatin doses in a testicular cancer patientwith acute renal failure. Journal of Oncology Pharmacy Practice 17: 265-269, No.3, Sep 2011. Available from: URL: http://dx.doi.org/10.1177/1078155209351761 -France 803064242
1
Reactions 17 Dec 2011 No. 13820114-9954/10/1382-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
